Search

Significant changes in platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) concentration have been observed in rabbit endometrium during the preimplantation period, but, under in vitro conditions, constitutive PAF biosynthesis by isolated endometrial tissues was not easily demonstrable. Relative changes in enzymes involved in the synthesis and metabolism of PAF in the tissues may account for this disparity. In addition, during this period of preimplantation, marked changes in PAF receptor concentration have been noted. The present study examines the factors that may modulate the metabolism of exogenous [3H]PAF in the endometrium of rabbits on day 6 of pregnancy. Since preferential [3H]PAF binding in situ by the glandular epithelial, but not by the stromal, cells was demonstrated, their cell-specific metabolism of exogenous [3H]PAF was also examined. After entry into the endometrial cell, [3H]PAF was rapidly metabolized by the sequential action of cytosolic Ca(2+)-independent acetylhydrolase to [3H]lyso-PAF and this was in turn acylated by membrane-associated transacylase to [3H]alkylacyl-glycerylphosphorylcholine. PAF resynthesis was not observed and, in stromal cells, there was a significant build-up of [3H]lyso-PAF, suggesting that lyso-PAF:acetyl-CoA acetyl-transferase may be a limiting factor. In the glandular epithelial cells, however, there was a significant accumulation of a neutral lipid without a significant build-up of [3H]lyso-PAF or [3H]PAF. The neutral lipid co-migrated with the product of phospholipase C-catalysed metabolism of PAF and authentic 1-O-hexadecyl-2-acetyl-glycerol. In addition, the elution times of phospholipase C digestion of C18 PAF and the neutral lipid produced by cellular metabolism of [3H]PAF, determined by gas chromatography/flame ionization detection, were similar. It seems that it is the synthesis of the neutral lipid from reacetylated [3H]lyso-PAF that prevented [3H]PAF accumulation under in vitro conditions. This is the first documentation of the synthesis of this lipid in the mammalian uterus. The lipid may serve as the precursor for de novo PAF synthesis in the glandular epithelial cells during endometrial proliferation.

[3H]PAF binding parameters (affinity constants and binding capacities) were estimated for endometrial membranes obtained on days 3 (when the morulae first enter the gravid uterus), 4, 5 and on day 6, about 22 h before the blastocyst becomes irremovably attached to the endometrium. The two-site receptor system which characterized the binding on a large proportion of purified membranes from days 3 (60%) and 6 (75%) had the following parameters: day 3, Kd1 (nM) 0.15 +/- 0.04, Bmax1 (pmol/mg protein) 0.04 +/- 0.01; Kd2 (nM) 17.60 +/- 6.40, Bmax2 (pmol/mg protein) 2.92 +/- 0.91 (n = 6), and day 6, Kd1 (nM) 0.33 +/- 0.06, Bmax1 (pmol/mg protein) 0.11 +/- 0.02; Kd2 (nM) 7.42 +/- 1.02, Bmax2 (pmol/mg protein) 1.75 +/- 0.31 (n = 3). The remaining membranes, including all preparations of days 4 and 5, exhibited only one class of binding sites which were unlike the putative type 1 PAF receptor. The most significant observations were the apparent pregnancy-associated changes in the parameters of the PAF binding sites. However, regardless of the type of PAF binding exhibited, all the binding sites bound GTP. [3H]PAF dissociation from bound complexes was biphasic at 25 degrees C. The rate constants were k-1, 0.27 +/- 0.09 min-1 and k-2, 3.45 +/- 1.19 x 10(-3) min-1, for the rapid and slow dissociating components, respectively. In view of the inability to resolve the experimental data from days 4 and 5 into multiple sites, and of the occurrence of receptor interconversions on days 3 and 6, it is postulated that there may be cell membrane macromolecular reorganization/remodeling of proteins and cytoskeleton as a result of the arrival of blastocyst in the uterus and/or the dynamic interplay of local uterine PAF and the hormonal milieux during the peri-implantation period of pregnancy.

The present study explores the ability of rabbit oviductal membranes to bind tritiated platelet-activating factor [3H]PAF on days 3 and 6 of pregnancy. Under optimal conditions (25 degrees C, 120 min) equilibrium saturation analysis revealed only one class of binding sites, characterized by Kd s(nM), 80.03 +/- 11.60 and 11.17 +/- 7.09 and Bmaxs, (pmol/mg protein), 5.25 +/- 2.23 and 1.08 +/- 0.22 (N = 3, mean +/- SEM) for ampullar membranes on days 3 and 6, respectively. The corresponding values for isthmic membranes were Kds, 86.56 +/- 12.01 and 52.43 +/- 30.49 and Bmaxs, 9.41 +/- 0.67 and 2.88 +/- 1.96 for days 3 and 6, respectively. Significant differences between days 3 and 6 were observed only in the binding affinities for the ampullar membranes and the binding capacities for the isthmic binding sites. [3H]PAF binding was inhibited in the following order of decreasing potency: lyso-PAF greater than PAF C18:0 greater than U66985 greater than PAF C16:0 for day 3 ampullar membranes; and lyso-PAF C16:0 greater than PAF C18:0 greater than U66985 greater than PAF C16:0 for day 6 ampullar membranes. These studies show the existence of specific oviductal membrane PAF binding sites, the binding parameters of which may be related to the stage of pregnancy, rather than to the spatial location along the oviduct. The relative proportion of endosalpinx to myosalpinx between the ampulla and isthmus may have masked inherent differences and account for the relatively low affinity binding. The physiological significance of oviductal membrane PAF binding is yet to be established.

High affinity receptors have been demonstrated for the potent phospholipid autacoid, platelet-activating factor (PAF C18:0; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) in a variety of tissues, including the endometrium. Because of the relative instability of PAF and our previous demonstration that lyso-PAF (1-O-alkyl-2-lyso-sn-glycero-3-phosphorylcholine), the major metabolite of PAF, displaced [3H]PAF from endometrial PAF receptor sites, we have examined the ability of bovine serum albumin (BSA) to prevent degradation of PAF and have characterized PAF and lyso-PAF binding sites in purified rabbit endometrial membranes isolated on Day 6 of pregnancy. In buffer containing the phospholipase A2 inhibitors, quinacrine (10 microM) and dibromoacetophenone (2 microM), and 0.25% BSA, 87.4 +/- 3.2% of added [3H]PAF C18:0 remained intact after incubation at 25 degrees C for 150 min. The metabolic products, lyso-PAF and 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine (alkylacyl-GPC), only amounted to 5.2 +/- 3.2 and 3.3 +/- 1.1, respectively. At the same concentration, rabbit serum albumin (RSA) also significantly protected [3H]PAF C18:0 from metabolism, but bovine gamma globulin (BGG) was ineffective. The presence of 0.25% BSA, however, did not protect [3H]lyso-PAF C18:0 from extensive catabolism: the major product formed was [3H]alkylacyl-GPC. Insignificant amounts of [3H]PAF were formed. Under the same conditions (25 degrees C, 150 min) in the presence of 0.25% BSA, saturation analysis revealed the presence of two types of PAF C18:0 receptors in the endometrial membranes. Type 1 sites had a Kd of 0.42 +/- 0.03 nM (mean +/- SD; n = 3) and binding capacity of 0.11 +/- 0.01 pmol/mg protein. Type 2 receptor sites had a Kd of 5.96 +/- 0.35 nM and a binding capacity of 1.59 +/- 0.22 pmol/mg protein. Thus, in the presence of BSA, the binding capacities of the two classes of receptors were markedly reduced compared to values generated previously in its absence. The Kd of the Type 1 sites was not significantly changed by the presence of BSA. A single class of saturable high-affinity binding sites was demonstrable for lyso-PAF C18:0: Kds ranged from 0.76 +/- 0.58 to 11.1 +/- 0.62 nM, depending on which method of analysis was used (Eadie-Hofstee, Scatchard-Rosenthal, or the Lundon nonlinear method). The binding capacities were equally varied, ranging from 0.15 +/- 0.08 to 15.17 +/- 4.95 pmol/mg protein.(ABSTRACT TRUNCATED AT 400 WORDS)

One of the earliest signs of endometrial preparation for blastocyst implantation is a localized increase in capillary permeability, an event that is essentially inflammatory in character and thought to be a prerequisite for subsequent decidual tissue formation. Platelet-activating factor (PAF), chemically identified as 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine, is a very potent vasoactive compound that recently has been implicated in the implantation process. In the present study, PAF binding sites are characterized in the rabbit uterus. A specific, reversible, saturable, and thermally labile binding of [3H]PAF to uterine membranes has been demonstrated, exhibiting multiple binding sites. The equilibrium dissociation constant (Kd) of the higher affinity binding site (type 1) was 3.6 +/- 0.4 nM (mean +/- SD) with a binding capacity (Bmax) of 3.4 +/- 1.6 pmol/mg protein. The second (lower affinity) binding site (type 2) had an apparent Kd of 114.6 +/- 13.5 nM and a Bmax of 164.3 +/- 17.6 pmol/mg membrane protein, under the conditions of maximal [3H]PAF binding, 25 degrees C, 150 min. Incubations at 4 degrees C for up to 3 h yielded only 30% of the Bmax observed at 25 degrees C. In crude and purified endometrial membrane preparations in which the PAF binding was predominantly located, the affinity of the binding for PAF was significantly higher than for the whole uterus, giving Kds of 1.5 +/- 0.8 and 0.8 +/- 0.5 nM; these latter values were not significantly different. However, the Bmax values of 3.9 +/- 0.9 pmol/mg protein and 376.8 +/- 163.3 fmol/mg protein for the two endometrial preparations, respectively, did differ significantly. Kinetic analysis at 25 degrees C resulted in a calculated Kd of 3.28 +/- 1.14 nM, which did not differ from the value for for the whole uterus at the same temperature, but was greater than for the endometrial preparations. Using 4 nM [3H]PAF to selectively label only the type 1 binding sites, the relative potencies of PAF and its antagonists in displacing [3H]PAF were lyso-PAF greater than CV3988 greater than PAF greater than U66985 greater than A02405 greater than BN52021 greater than U66982. The antagonists SRI 63,441 and L652,731 were ineffective in displacing [3H]PAF at up to 5000-fold molar excess of [3H]PAF. [3H]Lyso-PAF binding at 4 nM was displaceable by PAF. All cations tested, i.e. Ca2+, Mg2+, K+, Na+, and Li+, inhibited [3H]PAF binding. Serine hydrolase inhibitors, diisopropylfluorophosphate (DFP) and phenylmethylsulfonyl fluoride (PMSF), inhibited binding, but bacitracin, leupeptin, and antipain stabilized it.(ABSTRACT TRUNCATED AT 400 WORDS)